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Abstract
Background: Uncertainties associated with the delivery of treatment to moving organs might compromise the
accuracy of treatment. This study explores the impact of intra-fractional anatomical changes in pancreatic patients
treated with charged particles delivered using a scanning beam. The aim of this paper is to define the potential
source of uncertainties, quantify their effect, and to define clinically feasible strategies to reduce them.
Methods: The study included 14 patients treated at our facility with charged particles (protons or 12C) using intensity
modulated particle therapy (IMPT). Treatment plans were optimized using the Treatment Planning System (TPS) Syngo®
RT Planning. The pre-treatment dose distribution under motion (4D) was simulated using the TPS TRiP4D and the dose
delivered for some of the treatment fractions was reconstructed. The volume receiving at least 95% of the prescribed
dose (V95CTV) and the target dose homogeneity were evaluated. The results from the 4D dose calculations
were compared with dose distributions in the static case and its variation correlated with the internal motion
amplitude and plan modulation, through the Pearson correlation coefficient, as well the significant p-value.
The concept of the modulation index (MI) was introduced to assess the degree of modulation of IMPT plans,
through the quantification of intensity gradients between neighboring pencil beams.
Results: The induced breathing motion together with dynamic beam delivery results in an interplay effect, which
affects the homogeneity and target coverage of the dose distribution. This effect is stronger (ΔV95CTV > 10%) for
patients with tumor motion amplitude above 5 mm and a highly modulated dose distribution between and within
fields. The MI combined with the internal motion amplitude is shown to correlate with the target dose degradation
and a lack of plan robustness against range and positioning uncertainties.
Conclusions: Under internal motion the use of inhomogeneous plans results in a decrease in the dose homogeneity
and target coverage of dose distributions in comparison to the static case. Plan robustness can be improved by using
multiple beams and avoiding beam entrance directions susceptible to density changes. 4D dose calculations support
the selection of the most suitable plan for the specific patient’s anatomy.
Background
Treating pancreatic cancer is still an oncological chal-
lenge, it being one of the deadliest cancers worldwide [1,
2]. The use of photon irradiation is limited due to the
close proximity of the pancreas to the duodenum. Radio-
therapy with charged particles has been considered a
promising approach to improving patients’ overall survival
rates [3, 4]. This is because the sharp dose gradient may
allow for dose escalation. Nevertheless, uncertainties can
compromise the accuracy of this treatment to a greater
extent than is the case for conventional irradiation. These
uncertainties originate from anatomical changes between
treatment sessions (inter-fractional changes), the position-
ing of the patient, internal motion of the patient’s organs
during the delivery of treatment (intra-fractional), and
beam application uncertainties (range, position and width
of pencil beams). The considerable sensitivity of the ion
range to density changes in the beam-path reduces the
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tumor coverage, increases the dose inhomogeneity and
may cause an overdose in normal tissues.
Anatomical changes during the course of the treat-
ment, as well as tumor volume changes, intestine and
stomach filling and loss of adipose tissue, have been dis-
cussed in a recent publication [5].This study, however,
will address the impact of intra-fractional changes.
Intra-fractional anatomical variations, i.e. the induced
breathing motion, together with dynamic beam delivery,
has been shown to affect the dose distribution in terms
of homogeneity and target coverage [6]. This so-called
interplay effect must be quantified for each pathology
and facility-specific configuration of the beam delivery
system.
The integration of the motion information in the
treatment planning can be accomplished through a
time-resolved (4D) treatment planning system (TPS).
The 4DTPS simulates the temporal interference be-
tween the beam and the target motion, as given by an
external surrogate signal. Information about the patient is
taken from a 4DCT, while the beam delivery sequence
(BDS), i.e. number of particles per spot, intensity level and
beam pauses, is obtained from the accelerator control sys-
tem. When the BDS and breathing signal are measured
during treatment, a time-resolved dose calculation, known
as 4D Dose Reconstruction (4DDRec), may be performed.
When a simulated BDS is used, the dose determination
will be referred to as 4D Dose Simulation (4DDSim) [7].
When it comes to the challenging anatomical location
of pancreatic tumors, surrounded as they are by multiple
organs-at-risk (OARs), Intensity Modulated Particle
Therapy (IMPT) offers the benefit of allowing the dose
gradients to be increased between the OARs and the
tumor. However, IMPT has greater potential to facilitate
an increase in the effect of range and set-up uncertain-
ties than the Single Field Uniform Dose (SFUD) plans
[8]. In the context of photon therapy, the concept of a
modulation index was suggested as a way of quantifying
the modulation of the plan fluency [9]. In this study, this
parameter was adapted to scanned particle beams in
order to assess the robustness of IMPT plans and correl-
ate this with the interplay strength.
Methods
Patient cohort, imaging and immobilization technique
The breathing signals and beam delivery sequence of four-
teen pancreatic patients was monitored during irradiation.
The free-breathing planning CTs (CTplan) and 4DCTs
were acquired in the Somaton Sensation Open scanner
(Siemens, Erlangen, Germany), which performs a relative
phase-based reconstruction on the basis of the surrogate
signal of the motion-monitoring system AZ-733 V Re-
spiratory Gating System (Anzai Medical Co.,Ltd., Japan),
herewith referred to as “Anzai”. The 4DCT images were
sorted in eight standard motion states, using the breathing
phases (0%Ex, 40%Ex, 70%Ex, 100%Ex, 75%In, 50%In,
25%In and 20%In), where In corresponds to the inspir-
ation and Ex to the expiration process. The state 0%Ex is
the end-exhale and 100%Ex is the end-inhale state. A sam-
ple of the breathing signal, with the length of a typical
treatment, was acquired for the majority of the patients
during the CT session. A description of the set of patients
is available in Table 1.
Patients were immobilized, lying in a prone position,
using a vacuum mattress. This positioning resulted from
the need to use irradiation with posterior beams, in
order to reduce the inter-fractional anatomy variations in
the delivered dose [5], and a limitation of our beam deliv-
ery system at the time (no accurate delivery of beams
coming through the treatment table and indexing sup-
port). As a consequence of this prone immobilization, no
abdominal compression was applied and the patients were
imaged and irradiated under free-breathing.
The patient position was verified in-room by a 2D-3D
bony anatomy image registration between the orthogonal
X-ray taken at the isocenter and the DRRs calculated from
the planning CT. This enabled the translational and rota-
tional shifts to be determined meaning that the patient
could be accurately positioned on the treatment couch.
Treatment plan
Treatment planning was performed using the TPS Syngo®
RT Planning, which uses the LEM model for effective dose
calculation of the carbon ions and a fixed RBE factor of
1.1 for protons. In general, the plans were optimized using
IMPT for an initial dose of 45 Gy (RBE) - 54 Gy (RBE)
with an additional boost of 9 Gy (RBE) for some cases, as
specified in Table 1.
A scanning raster spacing of 3 × 3 mm in the lateral
direction, and an iso-energy slice spacing of 3 mm
water-equivalent was used for both the proton and car-
bon plans. The initial optimization parameter for the
pencil beam focus was 8 mm FWHM for the proton
beams (range between 8 and 30 mm depending on en-
ergy). For the carbon ion beams, however, a maximum
width of 10 mm FWHM was selected (range between 6
and 10 mm). These parameters were chosen in view of
the results from a previous study [10], in which the
interplay effects were minimized for an enlarged FWHM
of the pencil beam.
The selected beam configuration for each patient was
consequence of: (i) the superior inter-fractional robustness
of ion-beams posterior to the patient (according to [5]);
and (ii) the need to sparing the OARs (spinal cord and
kidneys) from unwanted doses. It was therefore treated
twelve of the fourteen patients with two posterior oblique
fields. The remaining two patients were treated with a dif-
ferent geometry due to OARs constraints. Treatment was
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nonetheless considered robust from the inter-fractional
point of view. The beam arrangements used are illustrated
in Fig. 1.
In all cases, plans were optimized to the PTV in order
to deliver the prescribed dose (Dpresc) to the CTV while
keeping the OARs doses below the dosimetric constraints
of the spinal cord, kidneys and intestines. Due to the short
distance between the tumor bed and the intestine, the pre-
scribed dose was not achieved for all the patients over the
entire CTV.
The PTV was assigned as an ITV expansion, by 7 mm
in beam direction and 5 mm laterally, while the ITV cor-
responds to the union of the CTV in each of the 4DCT
phases.
Image registration
The 4DCTs were rigidly registered using the bony anat-
omy of the CTplan. Deformable image registration (DIR)
was performed between the CTplan and the reference
4DCT state, CT0Ex, with the aim of contour propagation
using the vector field obtained. Moreover, each of the
4DCT states was registered against the CT0Ex with the
objective of deriving motion information during the cal-
culation of the time resolved dose distribution. The DIR
was performed with Plastimatch, using two successive
registrations with a B-Spline algorithm [11]. The quality
of the 4DCT DIR was assessed using the platform 3D
Slicer [12], in particular using the Registration Quality
Module [13], which was developed by external contribu-
tors as a set of tools that can be incorporated into 3D
Slicer. The evaluation was performed through visual in-
spection and numerical quantification, such as the deter-
minant of the Jacobian matrix (JD) of the vector field,
inverse consistency error (ICE) and mean absolute
difference.
Breathing signal and irradiation sequence
A pre-treatment acquisition of the breathing signal was
performed for twelve of the patients during the CTplan
acquisition session, as indicated in Table 1. For the other
two patients, the signal wasn’t acquired during the CT
session. As such, a standard Lujan motion with a patient
representative period of 3 s was considered [14].
The beam delivery structure was simulated using a tool
developed in-house, makeLmdout-MH [7, 15], based on
the synchrotron base data. The base data was obtained
from irradiated plans and considers the acceleration times,
energy dependence and random intensity fluctuations.
Table 1 Description of the set of patients, containing the information of the total dose prescription (T.dose), and per fraction (F. dose),
particle used (protons or carbon ions), existence of pre-treatment breathing signal (y- yes, n- no), number of treatment fractions with
recorded monitoring (Fx.monit). The median vector field length for the most extreme breathing state to end-expiration (0%Ex) CT is for
each patient 4DCT inside the ITV calculated (Max.MedianVFL). The adopted beam configuration (B.Config) follows the naming of the Fig. 1
Patient T.Dose
Gy (RBE)
Fx.dose
Gy (RBE)
Particle B.Config. Pre-tt breath.
signal
Fx.Monitor. Max.
MedianVFL
(mm)
H1 45 + 9 1.8 p B Y 2 8.7
H2 45 + 9 1.8 p B Y 1 6.9
H3 45 + 9 1.8 p C Y 1 4.6
H4 45 + 9 1.8 p B Y 3 3.1
H5 45 + 9 1.8 p B Y 4 3.3
H6 45 + 9 1.8 p B N 3 4.5
H7 54 2 p B N 1 4.6
H8 45 + 9 1.8 p B Y 1 4.1
H9 45 + 9 1.8 p B Y 1 4.7
H11 45 + 9 1.8 p B Y 3 5.0
H12 45 + 9 1.8 p A Y 6 12.7
H13 48 4 12C B Y 2 5.0
H14 48 4 12C B Y 1 3.1
H15 45 + 9 1.8 p B Y 1 2.2
Fig. 1 Beam configurations (A , B , C) adopted for these patients, in
which the patients were prone positioned
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The output of this tool is the random simulation of the ac-
celerator timing and intensity patterns for the given plan.
The inputs for the tool are the optimized treatment
plan, the breathing signal and the accelerator spill infor-
mation. The spill was characterized by the maximal
extraction time of 5.0 s, pause length and pause length
at the end-of-plan of 4.2 s (i.e. the time set to start a
new spill within the same IES, and the beam pause when
a IES is finished and the beam goes to the next IES,
respectively).
As output, a simulated BDS is obtained, which will be
given as input for the 4D dose calculation. In order to
describe the spectrum of possible irradiation scenarios
[16, 17], which results in different interplay patterns, a
temporal shift to the starting phase of the surrogate sig-
nal was applied, i.e. a temporal delay between the start-
ing of the breathing signal. This will correspond to the
irradiation of a different raster point in a defined breath-
ing phase. These shifts were spaced 500 ms in a total of
five different starting points of the irradiation for the
pre-treatment breathing signal and are given as input for
the 4DDSim.
During the patient irradiation, the Anzai system was
used to monitor motion. This system was connected to
a data acquisition system, known as the EtherCat system,
which correlated the breathing signal and the beam de-
livery temporal sequence of the accelerator in time. In
order to improve the acquisition statistics, the different
intensity rate from the proton and carbon beams was
considered and the sampling time was defined as
0.15 msec and 0.25 msec for protons and carbon ions re-
spectively. The calculation of 4DDRec was therefore per-
formed on the basis of the measured data (breathing and
irradiation sequence) during the irradiation of the indi-
vidual treatment fractions. The number of available frac-
tions with monitoring data is listed in Table 1.
Time resolved forward calculation of the dose distribution
The calculation of 4DDSim and 4DDReco was per-
formed using TRiP4D [17, 18]. The forward calculation
was based on the treatment plan information (raster
points, energies and beam focus), breathing signal and
the accelerator temporal pattern, either simulated or
measured, respectively. In addition, the vector fields ob-
tained for the DIR between each of the 4DCT states and
the reference state (CT0Ex) were given as input.
For both particles types, the forward dose calculation
followed the same parameters as in the Syngo® RT TPS,
differing for the proton plans only, where the physical or
absorbed dose was computed in TRiP4D. However, in
order to render negligible the effect of differences between
the beam models, the dose distribution was also calculated
in the static case, i.e. for the CTplan, and this dose distribu-
tion was taken as reference for the comparison.
Evaluation methods
The internal tumor motion of each patient was quanti-
fied using the vector field obtained from the DIR
between the CT0Ex and each of 4DCT states, and in
particular by measuring the median vector field length
(VFL) inside the ITV0Ex. The maximum of these values
was used as a quantification of the intra-fractional
tumor motion, generally corresponding to the CT100Ex.
The dose distributions, namely the static, the
4DDSim, and 4DDReco, were evaluated by taking as
metric the volume receiving at least 95% of the pre-
scribed dose (V95CTV) and the target dose homogen-
eity (HCTV = D5-D95).
Note that the 4DDSim corresponds to a set of dose
distributions, as representative of different interplay pat-
terns, resulting in the need to display the results as
mean and standard deviations and the DVHs as
band-DVHs.
In order to simplify the analysis, only the initial plan
was considered in the evaluation and the dose distribu-
tion for the boost plan was ignored.
In order to evaluate the impact of the dose modula-
tion on the plan robustness to intra-fractional
changes and interplay events, the normalized variation
of the number of particles per irradiation field was
evaluated (σnpfield). This parameter is given by eq. (1).
In (1) meannp,field is the mean number of particles
(np) for the respective field and σnp is the respective
root-mean-square of the mean of the squared differ-
ences between the number of particles at each IES
(i_ies) and raster point (i_rp) in the total number
iso-energy slices (nIES) and all the raster points in
each IES (nrp). The parameter nRP is the total num-
ber of raster points for the evaluated field.
σnpfield ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
nRP
Xi ies¼nIES
1
Xirp¼nrp
1
npi ies;i rp−meannp
 2r
meannp;field
¼ σnp
meannp;field
ð1Þ
In addition, to account for variations between
adjacent raster points, the concept of Modulation
Index (MI) was applied (eq. 2a). The MIs were calcu-
lated from the treatment plan information of each
field (MIfield), given by the raster points (rp) intensity
and location.
This index accounts with the changes in adjacent
raster points through the calculation of a function F
(eq. 2b). Here, for each raster point, the magnitude
of the difference between its intensity and the inten-
sity of neighboring raster points is calculated
through Δ = |Irp − Irp − 1|.
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MIfield ¼
Z ies¼nIES
ies¼1
F IESð Þδ ð2aÞ
where
F IESð Þδ ¼
NΔ>δ
nrp−1ð ÞIES
ð2bÞ
Secondly, the number of raster points (nrp) in each
IES, whose Δ is above a factor, δ, of the variation of its
IES is counted. This parameter is called N.
In brief, the function F quantifies the modulation of a
plan by the measure of changes in adjacent raster points
that exceed a certain fraction of the variation in each
IES. Hence, the area of this spectrum of deviations,
namely the area below the F function, gives the degree
of modulation i.e. MI.
The value of δ was selected as 1.2, in an iterative
process in a way to be sensitive to variations of the num-
ber of particles between adjacent raster points. For this
purpose, the value of δ was varied, and the resulting
function F was compared with the dose distribution per
beam. For clinically homogeneous plans, therefore the
function F has a small value, while it becomes gradually
larger for regions with larger dose gradients.
As both parameters are applied per field, a weighted
mean per plan for the different fields was used, giving the
parameters σnpplan and MIplan. The weighting was approx-
imated in view of the number of particles per beam.
To assess the correlation between the plan parameters
(V95CTV, HCTV, MIplan, σnpplan ) and the motion vector
magnitude, a multi-pairwise analysis was performed. For
this purpose, the Pearson linear correlation coefficient
(r) for each pair of variable and respective significance
(p-value) were calculated. Correlations with a p-value <
0.05 were considered significant. The entire statistical
evaluation was performed using R libraries [19].
Results
Internal motion
The median vector field length inside the ITV is shown
in Table 1. The median of the vector field for this set of
patients was (5.2 ± 2.7) mm, ranging from 2.2 to
12.7 mm. The main component of the motion was de-
tected in the cranio-caudal direction, followed by the
anterior-posterior direction. Figure 2 shows the vector
field for the patient H1.
Simulated time resolved dose distribution
In order to eliminate differences in dose calculation be-
tween TRiP4D and Syngo® RT the shown evaluation of
the 4D dose distributions is the comparison to the static
dose distribution also calculated with TRiP4D. Note that
the results for the 4DDSim and 4DDReco correspond to
the propagated CTV (CTV0Ex) contour from the CTplan
to the reference state CT0Ex.
Figure 3 illustrates the overall results. At first glance,
these results seem to show that a large number of plans
were strongly affected by beam interplay and displacements.
In the simulated cases, the variation of theV95CTV reached
values of up to − 28.0% with a mean of (− 7.6 ± 7.6)%. The
HCTV was also impaired, increasing from (15.9 ± 7.5)% in
the static case to (27.8 ± 8.5)% under motion.
Guiding the interpretation of these results, Fig. 4 shows
the DVH for the CTV of the reference dose distribution
(i.e. static) and of the set of 4D simulations, for the two
patients with the largest and smallest internal motion. Pa-
tient H12, due to a large internal motion (> 10 mm),
shows a broad DVH and a mean reduction of the V95CTV
of (− 15.8 ± 8.1)%. In contrast, patient H15, with a mean
tumor motion below 3 mm, shows a reduction in the
V95CTV of (− 6.7 ± 1.6)%, not being expected high dose
variations between different treatment sessions.
Our analysis shows that the dose degradation is af-
fected by the internal motion amplitude, with a strong
correlation between the motion amplitude within the
tumor and the standard deviation of the V95CTV varia-
tions relative to the static case (r = 0.86, p-value < 0.05).
However, we also see a non-significant correlation with
the mean V95CTV variations relative to the static case
(p-value > 0.05). The homogeneity dose, HCTV, was seen
to be more sensitive to motion, with the mean and
standard deviation differences strongly correlated (r =
0.61 and 0.77, respectively, p-value < 0.05).
The variation of the V95CTV is represented against the
internal motion amplitude in Fig. 5. The patients were
categorized in three groups: red (> 5 mm motion and >
5% of CTV dose degradation), yellow (large motion, i.e.
> 5 mm), and green (reduced impact on the dose distri-
bution and motion below 5 mm). The definition of these
limits represents the clinical practice at our facility.
This comparison suggests that as expected, patients
belonging to the red group show a reduction in the
Fig. 2 Vector field representation obtained from the deformable image
registration between the end- and full-exhale state for the patient H1.
The vector direction represents the deformation of voxel between CTs,
while the color indicate the magnitude of the deformation
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target coverage (reduced mean variation of the V95CTV
relative to the planned dose distribution) throughout the
entire course of treatment. Other patients however, such
as H7, do not support this hypothesis. In fact, we observed
that five patients for whom the motion amplitude was
below 5 mm the target suffered strong dose degradation
(yellow region). Another conclusion was that no patient
with a large internal motion (> 5mm) showed small dose
distribution degradation, i.e., no patients were observed in
the grey region in Fig. 5). This justifies the need to monitor
the motion amplitude for pancreatic patients throughout
treatment, applying an appropriate strategy to reduce its
impact (e.g. gating, robust optimization, rescanning, etc.).
Reconstructed time resolved dose distribution
The evaluation of the 4DDReco is also shown in Fig. 3,
where each green cross represents one treatment frac-
tion, overlaid with the static and 4DDSim results. This
figure indicates that the 4DDSim resulted in a good
approximation of the robustness of the plan for some
treatment fractions, while for others it can be used as
an indicator of the probability of seeing a reduction of
the CTV dose, either by the mean or width of the
boxplot of a set of simulations. The mean V95CTV
obtained from the 4DDSim strongly correlates with
the mean V95CTV from the set of 4DDReco (r = 0.87,
p-value < 0.05).
Fig. 3 Differences of the V95CTV for all the patients relative to the static dose distribution value. Each boxplot corresponds to the five simulated
interplay patterns from the 4DDSim, while the green crosses are the results from each of the treatment fraction where a 4DDReco was
performed. The red dashed lines define the 5% of variation relative to the static dose distribution and are here used to help in the detection of
the patients with major deviations
Fig. 4 DVH of the patient H12 (a) and H15 (b) for the CTV0Ex in the static case (red line) and for the set of 4DDSim as the blue band
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Figure 6 shows an example (patient H3) of the dose
distribution at one axial slice in the static, 4DDSim and
4DDReco situation, in which similar results to the
4DDSim and 4DDReco are seen, i.e. increase of the dose
inhomogeneities and reduction of the target coverage
dose. Nevertheless, other patients (such as H7 and H12)
exhibit a 4DDReco for a specific fraction outside the
predicted set of 4DDSim.
In general, patients with minor internal motion tend
to have more similar 4DDSim solutions, i.e. a small
interplay effect and therefore a small box width in Fig. 3.
However, the number of calculated simulations has lim-
ited value for the description of all possible interplay
patterns over and above those detected during the
4DDReco. It would be necessary to carry out further
simulations in order to cover a larger range of solutions.
Nonetheless, the 4DDSim results presented here, do in-
dicate whether a plan is or is not robust (high correl-
ation found between 4DDSim and 4DDReco).
From the visual inspection of the example dose distri-
butions, patient H3 shown in Fig. 6, one can observe
that the static plans were highly modulated for this pa-
tient. This effect was also observed for other patients.
This was associated with the dose optimization con-
straints of the OARs (mainly bowel) and target coverage,
which result in sharp dose gradients between the tumor
and the bowel contour. Hence, another studied conjec-
ture was the influence of the plan modulation on the
plan robustness to the breathing motion.
Impact of dose modulation
The normalized standard deviation of the number of par-
ticles (σnpplan), the modulation index and the variation of
the V95CTV and HCTV for all the patients and plans are
presented in Table 2. The significant linear correlations
between parameters are also seen here. The values per pa-
tient are available in the Additional file 1: Table S1.
An example of these MIfield variation patients, namely
H9 and H11, are presented in Fig. 7. These patients’
plans were selected because although both of them ex-
hibit the same amount of tumor motion (median VFL
Fig. 5 Mean difference of the V95CTV between the static and the 4DDSim versus the median vector field length inside the ITV. Red region
corresponds to large motion and consequently higher dose degradation, while green are patients with a robust dose distribution against intra-
fractional motion. The yellow region corresponds to patients where the motion amplitude is small (< 5 mm) but a reduction in the V95CTV is
demonstrated. A region without cases was found, grey area, which corresponds to any patients with large motion and small V95CTV variations
Fig. 6 Dose distribution in the transversal CT view for the patient H3 in the static (a), one of the simulated cases (b) and in the reconstructed
fraction (c). In yellow, blue and white, the GTV, CTV and ITV are displayed, respectively. The dose distribution was tailored in order to keep the
bowel doses (in purple) below the dosimetric constraints. In (a) is shown the planning CT, while in (b) and (c) is the CT0Ex
Batista et al. Radiation Oncology  (2018) 13:120 Page 7 of 11
inside the ITV), their 4D dose distribution varies signifi-
cantly. In Fig. 7, the function of the modulation, F, in
which the MIfield corresponds to the area below the
curve, is represented as a function of the IES for these
cases. In both cases, it was observed that the Syngo® RT
optimizer tended to have a strong modulation at tumor
borders, as a result of an optimization resembling distal
edge tracking. This effect is stronger; that is, more IESs
show a higher F value, when the tumor is in the
proximity of OARs, as in H11. Where this is not the
case, the shape of the function is similar to the one seen
for patient H9, where the first and last IES show a higher
F value and the values in-between F are close to zero.
Syngo® RT prioritizes the OARs constraints against the
tumor irradiation, resulting in an increase of the MIfield
when more constraints for the OARs are defined. More-
over, Syngo® RT uses a Broyden-Fletcher-Goldfarb-Shanno
(BFGS) algorithm to solve the optimization problem. The
solutions found by the BFGS algorithm, however, do not
include regularization of the number of particles between
neighboring raster points (regularization means a smooth-
ing of the distribution of particle numbers in the target
volume). This allows a greater difference between the
particle numbers in neighboring raster points. For the set
of patients the MIplan using the TPS Syngo® RT was 11.2 ±
6.2. In comparison, the common values obtained for the
other set of patients with the TPS TRiP4D and different
constraints were of 1.8 ± 2.6. This indicates that different
optimizers and different optimization constraints might
result in contrasting modulation levels. Having said
this, this comparison is beyond the scope of this study,
as only a certified TPS is used for clinical treatment
optimization.
The statistical evaluation of the data showed that σnpplan
and MIplan do not exhibit a significant linear correlation
with the variation of the HCTV or V95CTV (p-value > 0.05).
The difference between these two concepts (σnp and
MI) is that σnp ignores the location of the raster points
and may not be representative of intensity differences
between neighboring points and the plan modulation.
MI does not, however, include the energy information
and the use of multiple beams may diminish its signifi-
cance. Nevertheless, when this parameter is weighted by
the internal motion magnitude, it becomes highly corre-
lated with variations in the target coverage and inhomo-
geneity, r = 0.76 (p-value 0.002) and r = 0.75 (p-value
0.001), respectively for the standard deviation of the
V95CTV and HCTV differences.
A rough and intuitive method used to observe the
relationship between dose degradation under motion
and plan modulation is the comparison of the depth
profile of the dose distribution per radiation field. It was
observed that patients with a higher MI showed strong
dose gradients in the beam path for each individual field.
Table 2 Statistical analysis of the variation of the magnitude of the internal motion vector within the tumor, the variation of the
target coverage (indicated by the V95CTV parameter), the dose homogeneity (HCTV), average of the variation of the number of
particles per IES (σnp ) and Modulation Index (MIplan). The values presented correspond to the mean, standard deviation (std.) and
the two extreme cases (minimum and maximum) for the set of plans and patients. Each of these parameter was between each
other correlated, the Pearson correlation coefficient (r) and the significance p-value are presented. Correlations with p-values below
0.05 were considered not significant (n.a.)
Parameter Mean ± std. Min. Max. Correlation Parameter r
(p-value)
Internal Motion
vector magnitude
(mm)
5.2 ± 2.7 2.2 (H15) 12.7 (H12) Std. ΔV95 0.86 (< 0.05)
Std. ΔHCTV 0.77
(< 0.05)
ΔV954DDSim + 4DDReco (%) −6.9 ± 7.0 1.2 ± 1.0 (H11) −20.9 ± 3.9 (H7) σnp n.a.
(> 0.05)
MI n.a.
(> 0.05)
MI*motion 0.76
(< 0.05)
ΔHCTV4DDSim + 4DDReco (%) 11.7 ± 8.9 0.6 ± 1.0 (H11) 30.0 ± 5.9 (H12) σnp n.a.
(> 0.05)
MI n.a
(> 0.05)
MI*motion 0.75
(< 0.05)
σnp 1.7 ± 0.4 1.1 (H13) 2.6 (H8) – –
MI 11.2 ± 6.2 3.0 (H14) 22.5 (H11) – –
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As a consequence, when a large internal motion is
detected for these patients; it results in 4DDSim and
4DDReco with target under-dosage or OAR over-dosage
in at least some fractions.
Discussion
This study assessed the plan homogeneity and target
volume coverage of 14 patients with locally advanced
pancreatic cancer treated with either proton or carbon
ion therapy, focusing on intra-fractional motion induced
primarily by breathing. It was found that a larger num-
ber of treatment sessions deviated from the planned
dose distribution, i.e. larger ΔV95CTV (σΔv95) and plan in-
homogeneity (σΔH), when the tumor motion amplitude
increases (r = 0.86 and r = 0.77, respectively).
In view of the lack of real-time internal imaging during
irradiation, a surrogate signal was used for motion moni-
toring. The breathing baseline and phase shift, as well as
changes in the tumor volume and shape were therefore
disregarded in this study.
In terms of motion quantification, the set of patients
treated in the prone position showed a mean tumor
displacement of (4.8 ± 2.7) mm. Solla et al. [20] have also
used the 4DCT but with fiducial markers for motion
assessment, which resulted in a larger motion amplitude
of (8.5 ± 4.2) mm. This result is again justified by the
poor soft tissue contrast of the 4DCT. Tai et al. [21]
have measured pancreas motion by relying on 4DCT
data only and thus obtained (5.9 ± 2.8) mm, i.e. closest
to the one measured for this dataset. On the other hand,
where the motion was quantified by Fontana et al. [22]
on the basis of MRI data, in which case a better contrast
of the pancreas head, body and tail was seen, and pa-
tients were secured using immobilization systems (vac-
uum mattress, mask or abdominal compressor) median
values below 2.5 mm were measured.
The quality of the dose distribution using scanned
delivery is emphasized as an advantage over passive
delivery, as it serves to protect OARs [23]. Having said
that, the appearance of interplay can decrease the bene-
ficial impact [24]. Our results showed that six out of
fourteen patients showed at least one fraction with
V95CTV differences larger than 10%, relative to the static
case. On the other hand, the dose heterogeneity in-
creased from an HCTV of (15.9 ± 7.5) % to (27.8 ± 8.5) %.
These results might be associated with different factors,
such as: (1) patients exhibiting a tumor motion distance
larger than 5 mm; (2) dose distribution in the original plan
Fig. 7 Distribution along the iso energy slice (IES) of the modulation function of the number of particles for one of the treatment fields for the
patient H9 (a) and H11 (b)
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already compromises the target coverage due to the OARs
constraints and the V95CTV therefore corresponds to a
steeper DVH region; (3) the optimization strategy adopted
by the clinical TPS. With respect to the optimization strat-
egy, the plans were evaluated in terms of dose modulation
with the aim of correlating this with the dose degradation
under motion. Lomax et al. [8] have suggested that IMPT
offers potential for delivery with larger range and patient
set-up uncertainties compared to the SFUD. This is a con-
sequence of the three-dimensional variation of the beam
fluency. Moreover, the TPSs can reach different solutions
that might lead to similar dose distributions. This impact
would therefore be greater or smaller depending on the
optimization strategy and the defined constraints.
Webb et al. [9] have also suggested, in the context of
IMRT, that the modulation of a plan should be quanti-
fied, in order to understand how the TPS reached the
solution, i.e. how the inverse optimization is performed
to get the final dose distribution. The application of this
concept to this set of patients indicated that patients
exhibiting a higher MI and large motion were more
susceptible to strong interplay effects. When multiplied
by the motion amplitude, the MI was shown to be an in-
dicator of the plan robustness against inter-fractional
motion, with a significant linear correlation with the
V95CTV and HCTV variation (σv95 and σH) of r = 0.76 and
r = 0.75, respectively.
Nevertheless, the MI presented here cannot be used as
a sole indicator of the quality of the delivered dose dis-
tribution as this is dependent on other factors including
breathing frequency and amplitude, intensity of the
raster points with large dose uncertainty and changes in
patient anatomy. The MI simply offers additional infor-
mation enabling us to quantify the probability of dose
degradation in view of the interference between the
beam and the patient’s breathing. The MI may therefore
aide us in selecting between similar dose distributions.
In order to mitigate the impact of the intra-fractional
motion, strategies to improve the plan robustness must
also be added to the plan optimization process. Robust
optimization taking intra-fractional motion into account
will automatically lead to less modulation within the
fields and will thus result in improved dose coverage
[25]. Methods to reduce this impact may also be applied
to the treatment delivery (beam gating [26], rescanning
[27], or tracking [28]).
We are aware that our study has some limitations.
Firstly, our intra-fraction evaluation is based on just a
single 4DCT and the internal motion may vary
inter-fractionally. In addition, due to the external surro-
gate signal used, no baseline drifting and amplitude
changes of the tumor were taken into account. Sharp et
al. [29] have found that phase delays between the in-
ternal and external motion and baseline drifting for liver
patients with external surrogates would compromise the
gated beam delivery. Hence, these aspects must be quan-
tified and considered in future analysis.
In short, for some patients, the intra-fractional motion
has the potential to compromise the dose distribution.
Particular care should be taken when treating patients
with large tumor motion and strategies to reduce its
impact must be considered. Beam gating [26] or rescan-
ning [27] are the techniques which offer the greatest
potential for use in a clinical routine. More demanding
strategies, such as online adjustment of the individual
pencil beam energies [28] or 4D-optimised beam track-
ing [18] are not easily applied using the current beam
delivery system and TPS available in our facility.
Conclusion
The combination of inter-fractional and intra-fractional
sources of uncertainties might potentially be used to
mitigate the proposed clinical benefit of charged parti-
cles when treating pancreatic cancer. Breathing motion
monitoring and time-resolved dose calculation might
also help in the assessment of robust planning tech-
niques. Therefore, simple strategies such as the selection
of beam geometries and the restriction of the plan
modulation have been shown to improve the dose deliv-
ered to the patient under anatomical change, and might
improve the patient outcome.
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